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A series of β-carboline derivatives with amino or guanidinium were synthesized and evaluated in 
vitro against anti-Mycobacterium tuberculosis and for antiproliferative activities against nine human 
cancer cell lines. The compounds 1-(4-hydroxyphenyl)-3-carboxamide(ethylamine) β-carboline 
(24.9 μg mL-1) and 1-(4-methoxyphenyl)-3-carboxamide(ethylamine) β-carboline (26.9 μg mL-1) 
were the most active against M. Tuberculosis (MTB). Compounds 1-(4-hydroxyphenyl)-3-
carboxamide(ethylamine) β-carboline and 1-(4-methoxyphenyl)-3-carboxamide(propylamine) 
β-carboline, which had the same substituted groups, inhibited the growth of all human tumor cell 
lines with growth inhibitory activity (GI50) values from 1.37 to 9.20 mmol L-1. Also in this series, 
compounds 1-(4-hydroxyphenyl)-3-carboxamide(propylamine) β-carboline and 1-(3-nitrophenyl)-
3-carboxamide(propylamine) β-carboline demonstrated significant activity against NCI/ADR 
cells. Among compounds with a terminal guanidine group, compounds 1-(4-hydroxyphenyl)-3-
carboxamide(ethyl)guanidine β-carboline (27.8 μg mL-1) and 1-(3-nitrophenyl)-3-carboxamide(ethyl)
guanidine β-carboline (37.4 μg mL-1) demonstrated the greatest activity against MTB. Additionally, 
compounds 1-(4-methoxyphenyl)-3-carboxamide(ethyl)guanidine β-carboline (GI50 = 0.45 mmol L-1) 
effectively inhibited growth and was highly selective against NCI/ADR. The in silico study 
revealed that 1-(4-hydroxyphenyl)-3-carboxamide(ethylamine) β-carboline, 1-(4-methoxyphenyl)-
3-carboxamide(ethylamine) β-carboline, 1-(4-hydroxyphenyl)-3-carboxamide(propylamine) 
β-carboline, 1-(4-methoxyphenyl)-3-carboxamide(propylamine) β-carboline and 1-(3-nitrophenyl)-
3-carboxamide(propylamine) β-carboline compounds follow the rules established by Lipinski, 
suggesting that this compound has no problems with oral bioavailability. 
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Introduction
Tuberculosis (TB) exhibits high morbidity and 
mortality. The long-term treatment regimen can cause 
patients to be non-compliant in completing the treatment, 
thus leading to emergence of multidrug-resistant (MDR-
TB) and extensively drug-resistant (XDR-TB) TB strains. 
Infections caused by MDR-TB and XDR-TB do not 
respond to first-line drugs that are used to treat TB, and 
alternative treatment regimens include mostly injected 
drugs and prolonged treatments.1,2 Due to the appearance of 
resistant strains and given high toxicity of anti-tuberculosis 
drugs, to the need to develop new drugs that are more 
effective and less toxic than current drugs, which would 
reduce time and complexity of treatment, is urgent.3,4 The 
discovery of new drugs is also necessary for the treatment 
of cancer, because most chemotherapeutic agents exhibit 
severe toxicity and cause many undesirable side effects; 
additionally, current agents are very expensive, mutagenic, 
carcinogenic and teratogenic.5 Tuberculosis, caused by 
Mycobacterium tuberculosis (MTB),1 and cancer6 have 
affected human health for thousands of years and remain 
a major cause of diseases affecting public health around 
the world, and the possible interaction of mycobacterial 
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pathogens with cancer cells may be influenced by genetic 
alterations in the tumor cells.
Synthetic β-carboline derivatives exhibit a wide range 
of pharmacological activities, including antitumor and anti-
tuberculosis activities.7-14 Our research group demonstrated 
that β-carboline derivatives with various substituents at 
positions-1, 3 and 9 of the β-carboline skeleton presented 
significant in vitro antitumoral, antiviral, antitrypanosomal 
and antileishmanial activities.15-23 Other studies have shown 
that β-carboline derivatives with a methyl-substituted group 
at position-1 and a guanidinium group-terminated side chain 
at C-3 exhibited anti-HIV-1 activity in MT4 cells by hindering 
the essential interaction of the regulatory protein Tat with 
trans-activation response region (TAR).24,25 Some results 
cited above indicated that β-carboline derivatives containing 
4-hydroxyphenyl, 4-methoxyphenyl or 3-nitrophenyl group 
at C-1 showed potent anticancer activity for some of the 
human cancer cell lines tested. This led us to study novel 
β-carboline analogs that might serve as antitumoral and anti-
tuberculosis agents as part of our ongoing research program.
Based on the idea that the addition of appropriate 
substituents at positions-1 and -3 might result in more 
potent compounds, we synthesized novel 1-substituted-
phenyl-β-carboline with an amino or guanidinium group-
terminated side chain at C-3 and evaluated the in vitro anti-
tuberculosis, antiproliferative properties and in silico study.
Experimental
General procedure
1H and 13C nuclear magnetic ressonance (NMR) 
spectra were recorded on a Varian Mercury Plus (Palo 
Alto, EUA) spectrometer operating at 300 and 75.5 MHz, 
respectively, using deuterated dimethyl sulfoxide 
(DMSO-d6), chloroform (CDCl3) and methanol (CD3OD) 
as solvent, and tetramethylsilane (TMS) as internal 
reference. Infrared (IR) spectra were recorded as potassium 
bromide pellets on a BOMEM spectrometer model MB-
100 (Houston, USA). Melting points were determined in 
a Micro-Química apparatus MQAPF-301 model (Palhoça, 
Brazil) and are uncorrected. The reactions were monitored 
by thin layer chromatography (TLC) conducted on Merck 
TLC plates (Silica Gel 60 F254, Darmstadt, Germany). 
All reagents were purchased from commercial suppliers.
Preparation of 1-(substituted phenyl)-3-carboxamide-
ethylguanidine-β-carboline (4a-c)
The 1-(substituted phenyl)-3-carbomethoxy-β-carboline 
were obtained as previously reported.21 The 1-(substituted-
phenyl)-3-ethylamine-carboxamide β-carboline 2a-c 
were obtained by reaction of the methyl esters 1a-c 
(2.0 mmol L-1) with 1,2-ethylenediamine (6 mmol L-1) 
at room temperature, stirred for 36 h. The formed solids 
were collected by filtration. The 1-(substituted-phenyl)-3-
prophylamine-carboxamide β-carboline 3a-c were obtained 
by reaction of the methyl esters 1a-c (1.7 mmol L-1) with 
1,3-propanediamine (5 mmol L-1) in 25 mL MeOH/CHCl3 
was refluxed for 32 h. The formed solids were collected 
by filtration.26 
To a solution of S-methylisothiourea sulfate 
(0.5 mmol L-1) in water (1.5 mL) and 2 mmol L-1 NaOH 
(0.5 mL) was added a suspension of β-carboline-3-
ethylamine-carboxamide 2a-c at 0 °C. The mixture was 
kept under stirring, at room temperature by 1 h and 
later under reflux for 24 h, was again added a solution 
of S-methylisothiourea sulfate (0.5 mmol L-1) in water 
(1.5 mL) and 2 mol L-1 NaOH (0.5 mL) and reflux for 
24 h. The formed solids were collected by filtration and 
washed with cold water for obtained 1-(substituted phenyl)-
3-carboxamide-ethylguanidine β-carboline (4a-c).26 The 
characterization data of the compounds obtained are given 
bellow that corroborates with correlation spectroscopy 
(COSY), H1 detected multiquantum coherence (HMQC) 
and heteronuclear multiple-bond correlation (HMBC) 
two-dimensional NMR spectra.
1-(4-Hydroxyphenyl)-3-carboxamide(ethylamine) 
β-carboline (2a)
Yield 68%; mp 171-174 °C; IR (KBr) νmax / cm-1 
3090, 1684, 1480, 1460; 1H NMR (300 MHz, DMSO-d6) 
d 2.74 (t, 2H, J 6.0 Hz, CH2-ethyl), 3.07 (t, 2H, J 6.0 Hz, 
CH2-ethyl), 7.01 (d, 2H, J 8.7 Hz, Phenyl-H); 7.28 (t, 1H, 
J 7.0 Hz, H-6), 7.57 (td, 1H, J 7.7, 5.0 Hz, H-7), 7.67 (d, 
1H, J 8.4 Hz, H-8), 7.99 (d, 2H, J 8.7 Hz, Phenyl-H), 
8.37 (d, 1H, J 7.8 Hz, H-5); 8.73 (s, 1H, H-4); 13C NMR 
(75.5 MHz, DMSO-d6) d 41.2, 41.9, 112.1, 112.7, 115.7, 
120.3, 121.5, 121.8, 128.5, 129.2, 129.7, 130.0, 134.8, 
138.7, 141.4, 141.8, 157.9, 167.1.
1-(4-Methoxyphenyl)-3-carboxamide(ethylamine) 
β-carboline (2b)
Yield 74%; mp 180-182 °C; IR (KBr) νmax / cm-1 
3354, 3106, 1686, 1590, 860; 1H NMR (300 MHz, 
CDCl3/CD3OD) d 2.84 (t, 2H, J 6.0 Hz, CH2-ethyl), 3.87 
(t, 2H, J 6.0 Hz, CH2-ethyl); 3.95 (s, 3H, OCH3), 7.17 (d, 
2H, J 8.1 Hz, Phenyl-H), 7.36 (ddd, 1H, J 7.8, 7.5, 2.1 Hz, 
H-6), 7.58 (d, 1H, J 7.5 Hz, H-8), 7.61 (ddd, 1H, J 7.8, 7.5, 
2.1 Hz, H-7), 8.02 (d, 2H, J 8.1 Hz, Phenyl-H), 8.24 (d, 1H, 
J 7.8 Hz, H-5), 8.83 (s, 1H, H-4); 13C NMR (75.5 MHz, 
CDCl3/CD3OD) d 37.6, 39.3, 55.4, 113.1, 114.6, 115.1, 
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121.0, 122.4, 122.8, 130.8, 131.6, 132.3, 132.9, 133.6, 
139.5, 141.9, 142.0, 144.3, 162.5.
1-(3-Nitrophenyl)-3-carboxamide(ethylamine) β-carboline 
(2c)
Yield 66%; mp 172-175 °C; IR (KBr) νmax / cm-1 3190, 
1636, 1555, 1496, 1420; 1H NMR (300 MHz, CDCl3/
CD3OD) d 2.98 (t, 2H, J 6.0 Hz, CH2-ethyl), 3.63 (t, 2H, 
J 6.0 Hz, CH2-ethyl), 7.37 (m, 1H, H-6), 7.60 (m, 2H, 
H-8, Phenyl-H), 7.81 (t, 1H, J 7.8 Hz, H-7), 8.23 (dd, 1H, 
J 7.8 Hz, H-5), 8.37 (dd, 1H, J 7.0, 2.0 Hz, Phenyl-H), 
8.40 (d, 1H, J 7.0 Hz, Phenyl-H), 8.86 (sl, 1H, Phenyl-H), 
8,89 (s, 1H, H-4); 13C NMR (75.5 MHz, CDCl3/CD3OD) d 
39.9, 40.7, 112.4, 114.3, 120.8, 121.6, 121.7, 123.4, 123.5, 
129.1, 129.9, 131.1, 134.7, 135.0, 138.6, 138.9, 139.4, 
141.8, 148.5, 167.1.
1-(4-Hydroxyphenyl)-3-carboxamide(propylamine) 
β-carboline (3a)
Yield 72%; mp 180-182 °C; IR (KBr) νmax / cm-1 3226, 
1640, 1550, 1496, 1440; 1H NMR (300 MHz, DMSO-d6) d 
1.65 (q, 2H, J 6.3 Hz, CH2-prophyl), 2.65 (t, 2H, J 6.3 Hz, 
CH2-prophyl), 3.45 (q, 2H, J 6.0 Hz, CH2-prophyl), 7.00 (d, 
2H, J 8.1 Hz, Phenyl-H), 7.29 (t, 1H, J 7.2 Hz, H-6), 7.57 
(t, 1H, J 7.2 Hz, H-7), 7.67 (d, 1H, J 8.1 Hz, H-8), 8.02 (d, 
2H, J 8.1 Hz, Phenyl-H), 8.36 (d, 1H, J 8.1 Hz, H-5), 8.72 
(s, 1H, H-4); 13C NMR (75.5 MHz, DMSO-d6) d 32.8, 36.9, 
39.5, 112.0, 112.6, 115.6, 120.1, 121.3, 121.9, 128.3, 128.4, 
129.6, 130.1, 133.8, 139.7, 140.9, 141.5, 158.5, 164.9.
1-(4-Methoxyphenyl)-3-carboxamide(propylamine) 
β-carboline (3b)
Yield 60%; mp 188-193 °C; IR (KBr) νmax / cm-1 
3200, 1678, 1550, 1520, 1448, 1010; 1H NMR (300 MHz, 
DMSO-d6) d 1.64 (qt, 2H, J 6.6 Hz, CH2-prophyl), 2.64 
(t, 2H, J 6.6 Hz, CH2-prophyl), 3.44 (q, 2H, J 6.6 Hz, 
CH2-prophyl), 3.88 (s, 3H, OCH3), 7.18 (d, 2H, J 8.7 Hz, 
Phenyl-H), 7.30 (t, 1H, J 7.2 Hz, H-6), 7.58 (t, 1H, J 8.1 Hz, 
H-7), 7.67 (d, 1H, J 8.1 Hz, H-8), 8.14 (d, 2H, J 8.7 Hz, 
Phenyl-H), 8.38 (d, 1H, J 7.2 Hz, H-5), 8.75 (s, 1H, H-4); 
13C NMR (75.5 MHz, DMSO-d6) d 33.0, 36.9, 37.0, 55.4, 
112.3, 112.6, 114.2, 120.1, 121.3, 121.9, 128.4, 129.7, 
130.0, 130.1, 133.9, 139.8, 140.4, 141.6, 159.9, 164.5.
1-(3-Nitrophenyl)-3-carboxamide(propylamine) β-carboline 
(3c)
Yield 55%; mp 178-180 °C; IR (KBr) νmax / cm-1 3160, 
1686, 1534, 1474, 1440;
 
1H NMR (300 MHz, CD3OD) d 
1.65 (qt, 2H, J 6.5 Hz, CH2-prophyl), 2.65 (t, 2H, J 6.0 Hz, 
CH2-prophyl), 3.46 (q, 2H, J 6.0 Hz, CH2-prophyl), 7.33 
(t, 1H, J 7.5 Hz, H-6), 7.63 (m, 2H, H-8, Phenyl-H), 7.72 
(d, 1H, J 7.8 Hz, H-8), 7.91 (t, 1H, J 7.8 Hz, H-7), 8.33 
(dd, 1H, J 8.1, 1.5 Hz, Phenyl-H), 8.45 (d, 1H, J 7.8 Hz, 
Phenyl-H), 8.64 (d, 1H, J 8.1 Hz, H-5), 8.86 (s, 1H, H-4); 
13C NMR (75.5 MHz, CD3OD) d 32.8, 36.8, 37.0, 112.6, 
113.7, 120.4, 121.2, 122.2, 123.5, 123.6, 128.9, 130.2, 
130.4, 134.7, 135.1, 138.2, 138.9, 139.6, 141.6, 166.5.
1-(4-Hydroxyphenyl)-3-carboxamide(ethyl)guanidine 
β-carboline (4a)
Yield 30%; mp 176-178 °C; IR (KBr) νmax / cm-1 
3260, 1670, 1544, 1424, 1460, 1236;
 
1H NMR (300 MHz, 
DMSO-d6) d 3.22 ( t, 2H, J 6.5 Hz, CH2-ethyl), 3.49 (t, 2H, 
J 6.5 Hz, CH2-ethyl), 5.50 (s, 2H, NH2), 6.14 (s, 1H, NH), 
6.63 (s, 1H, NH), 7.05 (d, 2H, J 8.4 Hz, Phenyl-H), 7.28 
(t, 1H, J 7.5 Hz, H-6), 7.56 (t, 1H, J 7.5 Hz, H-7), 7.67 (d, 
1H, J 8.1 Hz, H-8), 8.05 (d, 2H, J 8.4 Hz, Phenyl-H), 8.37 
(d, 1H, J 7.8 Hz, H-5), 8.72 (s, 1H, H-4), 8.81 (s, 1H, NH); 
13C NMR (75.5 MHz, DMSO-d6) d 37.3, 40.5, 112.4, 113.0, 
116.0, 120.5, 121.5, 122.1, 128.6, 128.8, 129.9, 130.5, 
134.1, 139.6, 141.3, 141.7, 158.6, 159.6, 163.1.
1-(4-Methoxyphenyl)-3-carboxamide(ethyl)guanidine 
β-carboline (4b)
Yield 45%; mp 190-194 °C; IR (KBr) νmax / cm-1 3320, 
1670, 1550, 1520, 1448;
 
1H NMR (300 MHz, DMSO-d6) 
d
 
3.25 (q, 2H, J 6.0 Hz, CH2-ethyl), 3.45 (q, 2H, J 6.0 Hz, 
CH2-ethyl), 3.96 (s, 3H, OCH3), 5.54 (s, 2H, NH2), 6.18 (t, 
1H, J 7.5 Hz, NH), 7.22 (d, 2H, J 8.7 Hz, Phenyl-H), 7.34 
(t, 1H, J 7.0 Hz, H-6), 7.60 (t, 1H, J 7.5 Hz, H-7), 7.70 
(d, 1H, J 8.0 Hz, H-8), 8.20 (d, 2H, J 8.7 Hz, Phenyl-H), 
8.41 (d, 1H, J 8.1 Hz, H-5), 8.78 (s, 1H, H-4), 8.84 (t, 1H, 
J 7.5 Hz, NH), 11.81 (s, 1H, NH); 13C NMR (75.5 MHz, 
DMSO-d6) d 38.6, 40.3, 55.4, 112.3, 112.6, 114.2, 120.8, 
121.2, 121.9, 129.7, 129.9, 130.1, 133.8, 138.4, 139.6, 
140.5, 141.5, 159.0, 159.9, 165.1.
1-(3-Nitrophenyl)-3-carboxamide(ethyl)guanidine 
β-carboline (4c)
Yield 38%; mp 192-194 °C; IR (KBr) νmax / cm-1 
3204, 1668, 1530, 1520, 1448; 1H NMR (300 MHz, 
DMSO-d6) d 3.22 (m, 2H, CH2-ethyl), 3.42 (q, 2H, J 6.5 Hz, 
CH2-ethyl), 5.49 (s, 2H, NH2), 6.15 (t, 1H, J 7.0 Hz, NH), 
7.34 (t, 1H, J 7.0 Hz, H-6), 7.60 (d, 1H, J 7.8 Hz, H-8), 
7.62 (t, 1H, J 7.8 Hz, Phenyl-H), 7.95 (t, 1H, J 8.0 Hz, 
H-7), 8.39 (d, 1H, J 7.7 Hz, H-5), 8.45 (d, 1H, J 8.1 Hz, 
Phenyl-H), 8.65 (d, 1H, J 7.5 Hz, Phenyl-H), 8.86 (s, 1H, 
Phenyl-H), 8.89 (s, 1H, H-4), 8.90 (s, 1H, NH), 12.02 (s, 
1H, NH); 13C NMR (75.5 MHz, DMSO-d6) d 38.7, 40.5, 
112.6, 113.8, 114.2, 120.4, 121.2, 122.3, 123.4, 123.6, 
128.9, 130.4, 130.5, 134.4, 135.5, 138.1, 138.9, 140.1, 
141.7, 148.3, 159.01, 164.9.
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Anti-Mycobacterium tuberculosis activity
M. tuberculosis H37Rv (ATCC27294) strains were 
grown in Ogawa-Kudoh (OK) medium for 10 days at 
37 °C. For testing, aliquots were removed and cultured 
in Middlebrook 7H9 broth (Difco, Sparks, USA) 
supplemented with oleic acid, bovine serum albumin, 
dextrose and catalase (OADC enrichment BBL/Becton-
Dickinson); 0.5% glycerol was added as a carbon source 
and 0.5% Tween 80 was added to prevent the appearance 
of lumps. The culture was maintained for 15 days at 37 ºC. 
The bacterial suspensions were prepared and adjusted to 
the No. 1 of the McFarland scale.
 Stock solutions of the test compounds were 
solubilized in dimethyl sulfoxide (DMSO) (Sigma-
Aldrich, St. Louis, USA) and diluted in Middlebrook 7H9 
broth (Difco, Sparks, USA) supplemented with OADC 
enrichment BBL/Becton Dickinson. Rifampicin and 
isoniazid were solubilized according to the manufacturer’s 
recommendations (Sigma-Aldrich, St. Louis, USA) and 
used as positive controls.
 Antimycobacterial activity was determined using the 
resazurin microtiter assay (REMA).27 Briefly, 100 μL of 
supplemented Middlebrook 7H9 broth (Difco, Sparks, 
USA) was dispensed into each well of a sterile flat-bottom 
96-well plate; then, serial dilutions of the test compounds 
(0.98-250 μg mL-1) and reference drugs (0.004-1 μg mL-1) 
were prepared. One hundred microliters of bacterial 
suspension (5 × 105 UFC mL-1) was then added to each 
well. Plates were incubated for 7 days at 37 °C, after was 
added 30 μL of resazurin (Sigma-Aldrich, St. Louis, USA) 
in sterile water (0.01%) in whole plate, and the samples 
were incubated for 24 h at 37 °C. 
The change in absorbance, at 492 nm wavelength, was 
measured using a microplate reader TP-Reader (Thermo 
Plate®, Männedorf, Switzerland). Each compound was 
analyzed in triplicate on alternate days. The minimum 
inhibitory concentration (MIC) was defined as the lowest 
concentration that resulted in 90% inhibition of the growth 
of M. tuberculosis.28 MIC values were used to classify a 
compound’s activity as follows: inactive, > 150 μg mL-1; 
moderate, between > 10 and < 100 μg mL-1; and active, 
< 10 μg mL-1.
In vitro antiproliferative assay
The tested compounds were evaluated in vitro against 
a nine-cell line panel comprising melanoma UACC-62, 
breast MCF7, lung NCI-460, leukemia K-562, ovarian 
OVCAR, prostate PCO-3, colon HT29, renal 786-0 and 
adriamycin drug-resistant ovarian cancer NCI/ADR cells. 
The tests were performed using the colorimetric method 
with sulforhodamine B according to the National Cancer 
Institute (NCI) standard protocol; doxorubicin was used as 
a positive control.29 Assays were performed in a 96-well 
plate using four serial 10-fold dilutions (0.25-250 μg mL-1) 
for each test compound. The anticancer activity was 
determined based on concentration-response curves, and 
three concentration response parameters, growth inhibitory 
activity (GI50), growth inhibition (TGI) and cytotoxic 
activity (LC50) were calculated. The response parameter 
GI50 refers to the drug concentration that produces 50% 
reduction of cell growth when compared to untreated 
control cells. The TGI and LC50 parameters refer to the 
drug concentrations required for total growth inhibition and 
for 50% cell mortality, respectively. Compounds with GI50 
values < 100 μmol L-1 were considered active.
In silico study
The in silico computational study of compounds were 
performed to determine Lipinski’s rules of five30 (hydrogen 
bond donors ≤ 5; hydrogen bond acceptors ≤ 10; molecular 
weight ≤ 500; the Log P is ≤ 5), topological polar surface 
area (TPSA) and percentage of absorption (%ABS). 
Calculations were performed using Molinspiration 
online property calculation toolkit software31 and 
OSIRIS property explorer software.32 The percentage of 
absorption was estimated using the following equation: 
%ABS = 10 – [0.345 × TPSA]. 
Results and Discussion
Chemistry
The synthetic pathway for the preparation of 
1,3-disubstituted β-carbolines is presented in Scheme 1. The 
methyl esters in 1a-c were prepared by a Pictet-Spengler 
condensation of L-tryptophan with the appropriate aromatic 
aldehydes in acidic media, subsequent esterification of 
the resulting carboxylic acids with methanol and sulfuric 
acid, and oxidation with sulfur in refluxing xylene.22 
Compounds 2a-c and 3a-c were obtained by the reaction 
of β-carboline methyl ester with 1,2-ethylenediamine 
and 1,3-propanediamine, respectively, and resulted in an 
amino group-terminated side chain at C-3. Finally, the 
coupling of β-carboline carboxamide derivatives 2a-c 
with S-methylisothiourea yielded compounds 4a-c, which 
include a terminal guanidinium group. 
The novel compounds 2a-c, 3a-c and 4a-c were 
characterized using 1H and 13C NMR spectroscopy, as 
detailed in the Experimental section. The 1H NMR spectra 
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of carboxamides 2a-c and 3a-c showed additional signals at 
dH 1.64-3.95 (reflecting the integration of two protons) and 
at dH 7.01-8.94 (corresponding to aromatic hydrogens). The 
presence of the ethylamine or propilamine carboxamide 
in position C-3 group was confirmed by 13C NMR, which 
showed signals at dc 32.8-41.9 (CH2) and dc 162.5-167.1 
(C=ON). Derivatives 4a-c was characterized by the 
presence of an additional signal at dc 159.01-159.90, 
corresponding to the guanidinium group.
Anti-Mycobacterium tuberculosis activity (MTB)
Derivatives 2a-c, 3a-c and 4a-c were evaluated 
in vitro for their antimycobacterial activity against 
M. tuberculosis H37Rv (ATCC 27294) using the REMA 
method.27 The MIC values (μg mL-1 and μmol L-1) were 
measured with respect to two standard antitubercular 
drugs, isoniazid (INH) and rifampicin (RFP), and the 
screening results are presented in Table 1. Among 
the nine compounds evaluated against MTB, seven 
presented moderate activity, with MIC values ranging 
from 58.3-24.9 μg mL-1; in particular, compounds 2a 
(24.9 μg mL-1), 2b (26.9 μg mL-1), 4a (27.8 μg mL-1) 
and 4c (37.4 μg mL-1) presented interesting activity. 
Compounds 2a and 2b, which had p-hidroxyphenyl and 
p-methoxyphenyl substituents, respectively, at position-1 
and ethylenediamine moieties at C-3 were the most active 
derivatives in this series. The length of the terminated 
side chains affected the activities of these compounds. 
Substituting the guanidinium group led to reduced 
activity (compare compounds 2a and 4a). The effect 
of the guanidinium group was particularly significant 
when comparing compounds 2c (57.9 μg mL-1) and 4c 
(37.4 μg mL-1). The substituents at positions-1 and 3 
strongly affected anti-MTB activities of these compounds.
Earlier studies reported the synthesis and investigations 
of the antimycobacterial activity, e.g., guanidinium-modified 
compounds, which demonstrated potent antitubercular 
activity against M. tuberculosis, aminopyrimidine 
derivatives exhibit moderate to potent anti-MTB activity, 
with MIC values ranging from 12.5-3.12 μg mL-1.33 
The introduction of an ethylguanidinium group at the 
upper rim resulted in high antimycobacterial activities 
for the unsubstituted, 5,5’-dimethyl-2,2’-bipyridyl and 
4,4’-dimethyl-2,2’-bithiazolyl analogs, with MIC values 
of 1.51 and 2.69 μg mL-1, respectively, values that were 
similar to those of current commercially available anti-
tuberculosis agents.34
Antiproliferative activity
The antiproliferative activities of the synthesized 
1,3-disubstituted β-carbolines derivatives (2a-c, 3a-c and 
4a-c) were evaluated in vitro against nine human tumor 
cell lines. The results for compounds 2a-c and 3a-c, 
Scheme 1. Synthetic route for the preparation of the β-carbolines derivatives. Reagents and conditions: (a) 1,2-ethylenediamine, at room temperature, 
36 h or 1,3-propanediamine, CHCl3/MeOH, reflux, 32 h (55-72%); (b) S-methylisothiourea, 2N NaOH, 4 °C to room temperature, reflux, 48 h (30-45%).
Table 1. Anti-Mycobacterium tuberculosis H37RV activity of compounds 
2a-c, 3a-c and 4a-c
Compound R n MIC
a / 
(μg mL-1)
MIC / 
(μmol L-1)
2a 4-OH 2 24.9 75.4
2b 4-OCH3 2 26.9 74.6
2c 3-NO2 2 57.9 153.5
3a 4-OH 3 > 250 > 500
3b 4-OCH3 3 58.3 155.7
3c 3-NO2 3 > 250 > 500
4a 4-OH 2 27.8 74.4
4b 4-OCH3 2 57.5 142.6
4c 3-NO2 2 37.4 88.3
Isoniazid – – 0.05 0.3
Rifampicin – – 0.01 0.01
aMIC = minimum inhibitory concentration (REMA assay), values quoted 
are the means of results for triplicate samples.
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which were amino group-terminated at C-3, demonstrated 
that compounds 2a and 3b, with p-hydroxyphenyl and 
p-methoxyphenyl groups, respectively, at position-1, 
inhibited growth in all human tumor cell lines with GI50 
values ranging
 
from 1.37-9.20 μmol L-1. Also in this series, 
compounds 3a (GI50 = 0.33 mmol L-1, TGI = 50.28 mmol L-1) 
and 3c (GI50 = 0.71 mmol L-1, TGI = 11.08 mmol L-1, 
LC50 = 26.62 mmol L-1) showed significant activity and 
high selectivity against adriamycin drug-resistant ovarian 
cancer cells (NCI/ADR) (Tables 2 and 3).
The compounds with terminal guanidinium 
groups, including compound 4b (GI50 = 0.45 mmol L-1; 
TGI = 72.09 mmol L-1) effectively inhibited growth and 
was highly selective against adriamycin drug-resistant 
ovarian cancer cell lines (NCI/ADR) when compared 
with compounds 2a-c, which are amino group-terminated. 
However, the guanidinium-terminated compounds did not 
demonstrate any important interaction that could account 
for the cell growth inhibition. Substituting the phenyl group 
with electron-donating substituents at position-1 influenced 
each series differently.
A previous study evaluated the in vitro antitumor 
activities of several benzenesulfonamide derivatives 
with various substituted aminoguanidine groups. 
Compound 1-allyl-2-[4-chlorophenylcarbamoyl)-2-
methylthiobenzenesulfonyl]-3-(5-nitrofurfurylideneamino) 
exhibited remarkable activity against 21 human tumor 
cell lines representing leukemia and melanoma and 
lung, colon, ovarian, renal, prostate and breast cancers 
(GI50 = 0.3-3.0 μmol L-1).35
Table 2. In vitro cell growth inhibition (GI50) of compounds 2a-c, 3a-c and 4a-c against neoplastic cells
Compound R n
GI50a / (μmol L-1)
UACC-62 
melanoma
MCF7 
breast
NCI-460 
lung
K-562 
leukemia
OVCAR 
ovarian
PCO-3 
prostate
HT29 
colon
786-0 
renal
NCI/ADR 
ovarian-
resistant
2a 4-OH 2 5.15 9.55 9.64 2.93 9.20 8.69 4.27 9.64 8.18
2b 4-OCH3 2 38.75 44.49 44.49 53.07 17.14 *c > 100 33.11 8.36
2c 3-NO2 2 10.34 11.72 88.26 > 100 9.36 * 25.82 21.64 2.42
3a 4-OH 3 25.14 16.19 13.59 13.01 22.75 23.57 23.57 18.71 0.33
3b 4-OCH3 3 9.66 6.98 7.35 5.20 7.09 2.39 9.02 4.40 1.37
3c 3-NO2 3 43.22 23.94 55.16 18.89 16.76 11.18 27.48 27.48 0.71
4a 4-OH 2 > 100 > 100 –b – > 100 – – 3.61 > 100
4b 4-OCH3 2 95.93 35.46 27.17 63.41 39.94 15.54 75.64 63.41 0.45
4c 3-NO2 2 51.85 99.17 > 100 31.03 87.51 91.82 25.02 31.03 1.71
aGI50 = growth inhibitory activity; bnot determined; cnot tested.
Table 3. Total growth inhibition (TGI) and lethal concentration (LC50 - in parentheses) of compounds 2a-c, 3a-c and 4a-c (μmol L-1)
Compound R n UACC-62 
melanoma
MCF7 
breast
NCI-460 
lung
K-562 
leukemia
OVCAR 
ovarian
PCO-3 
prostate
HT29 
colon
786-0 
renal
NCI/ADR 
ovarian-
resistant
2a 4-OH 2 15.44 
(37.5)
38.27 34.32 23.87 24.75 
(51.7)
24.75 
(74.42)
73.52 24.75 
(64.37)
24.75
2b 4-OCH3 2 > 100 > 100 > 100 > 100 > 100 *b > 100 > 100 26.45
2c 3-NO2 2 20.35 
(70.93)
22.41 
(43.42)
> 100 44.27 19.33 
(30.85)
* > 100 87.41 79.13
3a 4-OH 3 –a 42.55 – 36.01 – >100 – – 50.28
3b 4-OCH3 3 – 15.38 
(32.8)
20.83 
(51.25)
15.38 
(37.3)
21.47 
(46.84)
10.56 
(35.2)
21.47 
(49.15)
16.71 
(46.84)
11.97 
(28.94)
3c 3-NO2 3 > 100 > 100 – > 100 > 100 43.09 > 100 > 100 11.08 
(26.62)
4a 4-OH 2 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100
4b 4-OCH3 2 – > 100 > 100 > 100 > 100 > 100 > 100 > 100 72.09
4c 3-NO2 2 90.86 – – 55.07 – – 99.28 > 100 > 100
aNot determined; bnot tested.
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Lipinski’s rule of five
The drug-likeness concept helps optimize the 
pharmacokinetic properties of a compound, such as 
absorption, distribution, metabolism and excretion (ADME) 
in the human body.36 Lipinski’s rule of five is a refinement 
of drug-likeness and is used to predict whether a chemical 
compound will have pharmacological or biological activity 
as an orally active drug in humans. This rule was formulated 
based on the observation that most medication drugs are 
relatively small and lipophilic molecules.33 The results 
of the analysis are shown in Table 4 and indicate that the 
compounds are in agreement with the values determined by 
Lipinski, except 4a-c derivatives, which showed the number 
of hydrogen bond donors (nHBD) > 5, in violation of the 
Lipinski rules. The calculated percent absorption (%ABS) 
of all compounds ranged from 51.90-76.91%, indicating 
good cell membrane permeability. Another important 
factor is obtained by the volume analysis and TPSA by the 
compounds showed lower than 140 Å² indicating that these 
derivatives have good absorption in the intestine, except the 
compound 4c (TPSA = 165.51). The compounds 2a-c, 3a-b 
and 4a-c exhibited good solubility (Log S = –3.87 to –4.98), 
except the compound 3c which showed a value of Log S 
less than –5. Compounds with high solubility are easily 
metabolized and eliminated from the body, thus resulting in 
a lower probability of adverse effects and bioaccumulation.
Conclusions
Thus, our results showed for the first time the synthesis 
and antitumor and anti-MTB activity of compounds with an 
amino or guanidinium group-terminated side chain at C-3 
of a 1-substituted-phenyl-β-carboline nucleus. Compounds 
2a, 2b and 4a were the most active against M. Tuberculosis 
H37Rv (ATCC27294). Compound 2a and 3b demonstrated 
promising antiproliferative activity for all cancer cell lines. 
Eight compounds inhibited the cell growth of adriamycin 
drug-resistant ovarian (NCI/ADR), showed activity and 
high selectivity for the 3a, 3c and 4b. Compound 2a 
demonstrated promising antiproliferative and anti-MTB 
activity, in addition to follow as established Lipinski’s rule 
of five, suggesting that this compound has no problems with 
oral bioavailability, and indicates good permeability a in 
the plasma membrane of the cell, which may represent a 
precursor to development of new molecules. Further studies 
are required to explore the mechanism of action of these 
compounds in detail.
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